Disease Associations (HCV/HCC)
"Risk Factors for Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis Type C after Interferon Therapy."
Published in Hepatitis Weekly, July 21st, 1997
According to an abstract submitted by the authors to the 97th Annual Meeting of the American Gastroenterological Association, held May 11-14, 1997, in Washington, DC, "Background: Interferon (IFN) therapy for chronic hepatitis type C makes HCV-RNA in serum eliminate, resulting in prevention of development to liver cirrhosis. However it was unknown whether IFN therapy inhibited the development of hepatocellular carcinoma (HCC) after cessation of therapy or not. Recently it has been reported that HCC developed not only in the IFN nonresponders but also in the IFN responders. The aim of this study was to investigate the risk factors for the development of HCC in the patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1997-07-21)
More Articles from Hepatitis Weekly
- Etiology (HCV)
Whole Blood Better Than Plasma for Identifying Antibody-Negative HCV - Hepatitis C Virus
ELISA Screening Over-Estimates Infection - Hepatitis A and C
CDC Issues New Fact Sheet - Immunization (HAV)
Children In Areas With High HAV Rates Should Receive Hepatitis A Vaccine - Infection Control (HBV)
Vaccine Program Has Lowered Liver Cancers in Children - International (Africa)
Controversial Report Warns of Recycled Glove Use in Kenyan Hospital - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
